Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830233 | 0.89 | DDB1 (0.45) | DDB1CRBNHSD11B1CYP19A1NPC1 | |
| SCHEMBL1831946 | 0.81 | DDB1 (0.46) | DDB1CRBNHSD11B1CYP19A1NPC1 | |
| SCHEMBL8103340 | 0.73 | DDB1 (0.43) | DDB1CRBNHSD11B1CYP19A1NPC1 | |
| SCHEMBL29013938 | 0.71 | DDB1 (0.52) | DDB1CRBNHSD11B1CYP19A1NPC1 | |
| SCHEMBL8676314 | 0.71 | DDB1 (0.51) | DDB1CRBNHSD11B1ALDH1A1MAOB | |
| SCHEMBL29016897 | 0.71 | DDB1 (0.61) | DDB1CRBNHSD11B1CYP19A1KMT2A | |
| SCHEMBL8676485 | 0.71 | DDB1 (0.51) | DDB1CRBNHSD11B1ALDH1A1MAOB | |
| SCHEMBL19050135 | 0.71 | DDB1 (0.51) | DDB1CRBNHSD11B1ALDH1A1MAOB | |
| SCHEMBL7268376 | 0.70 | KMT2A (0.45) | DDB1CRBNHSD11B1CYP19A1NPC1 | |
| SCHEMBL11790156 | 0.69 | HSD11B1 (0.57) | DDB1CRBNHSD11B1ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| US-20180340174-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | NANOCORE APS (DK) | 2018-11-29 | — | — | US | disclosed |
| EP-3218479-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | Nanocore ApS (DK) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016074683-A1 | METHOD FOR IDENTIFICATION OF MOLECULES WITH DESIRED CHARACTERISTICS | LUNDORF PEDERSEN MATERIALS APS (DK) | 2016-05-19 | — | — | WO | disclosed |
| US-9040526-B2 | Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2534158-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120295899-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-22 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| WO-2011100227-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295899-A1 | BENZYLPYRROLIDINONE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | DDB1 1558/4885CRBN 780/4885HSD11B1 848/4885 |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | DDB1 163/4885CRBN 2397/4885HSD11B1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.